ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and its place in pharmaceutical development, and central nervous system drug discovery in particular. Assays that have been developed in response to specific needs and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of absorption and toxicity are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“Worse, at this poor level of accuracy, large numbers of compounds that would perhaps have been safe in human patients, but show toxicity in animals, would be removed from development without going forward into human trials [27].”
BackgroundHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 1×
“The potential of stem cells to differentiate into cell lines of many different lineages may be exploited to develop human and animal stem-cell-derived systems for major organ systems [45].”
BackgroundMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 1×
“Three-dimensional models have been developed for cell-based therapies, including micropatterned co-cultures of human liver cells that maintain the phenotypic functions of the human liver for several weeks [43], which should provide more accurate information about toxicity when used in ADMET screening.”
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664 · cited 1×
“The consequent overload resulted in increases in plasma terfenadine to levels that caused cardiac toxicity [6].”
BackgroundO’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0091-3 · Cited by 609
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417 · cited 1×
“Now, lack of efficacy and human toxicity are the major reasons for failure [12].”
BackgroundDrug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction
Myung, Y., de Sá, A. G. C., & Ascher, D. B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae254 · Cited by 337
A Bayesian Approach to in Silico Blood-Brain Barrier Penetration Modeling
Martins, I. F., Teixeira, A. L., Pinheiro, L., & Falcao, A. O. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300124c · Cited by 331
Drug discovery through stem cell-based organoid models
Ranga, A., Gjorevski, N., & Lutolf, M. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.006 · Cited by 195
“The process of ADMET evaluation (adsorption, distribution, metabolism, excretion, toxicology), while having undergone significant improvements in the last 15 years [2], could still be considered one of themain bottlenecks in the drug development process and could afford the greatest return on technological innovations…”
BackgroundFraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119
“cells or tissues, respectively (Bass et al. 2009; Tsaioun et al. 2009).”
Metadata
- Authors
- Tsaioun, K., Bottlaender, M., Mabondzo, A., & the Alzheimer's Drug Discovery Foundation
- Venue
- BMC Neurology
- Published
- 2009
- Volume
- 9
- Issue
- Suppl 1
- Pages
- S1
- ISSN
- 1471-2377 (ISSN-L)
- OpenAlex
- W1969927552
- Cited by
- 103
- References
- 10
- Type
- conference abstract
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. https://app.cochat.ai/papers/10.1186/1471-2377-9-s1-s1
- The paper
- Tsaioun, K., Bottlaender, M., Mabondzo, A., & the Alzheimer's Drug Discovery Foundation. (2009). ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurology. https://doi.org/10.1186/1471-2377-9-s1-s1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.